Publicado el

Even Dialysis Patients Can Maintain COVID Antibodies for Months

Loading

“The vast majority of dialysis patients infected with COVID-19 maintained antibodies for at least 6 months, a new study found.

In a prospective analysis of over 2,000 adults on dialysis, 93% of seroprevalent patients reached an assay detectable response — a SARS-CoV-2 receptor-binding domain (RBD) IgG index value of 1 or higher — and maintained this level throughout a 6-month follow-up, reported Shuchi Anand, MD, of Stanford University in California, and colleagues.

On top of that, 60% of patients had IgG index values of 10 or greater — classified as high — the group wrote in Annals of Internal Medicine. Of these patients, 76% maintained this antibody level throughout the 6-month follow-up.”

Read more, here.

Loading
Publicado el

Safety Concerns Turn FDA Panel Thumbs Down for Novel CKD-Anemia Drug

Loading

An FDA advisory committee almost unanimously agreed that the risks were just too high for the chronic kidney disease (CKD)-related anemia drug roxadustat in any patient population.

In a 13-1 vote Thursday, members of the Cardiovascular and Renal Drugs Advisory Committee felt that although there’s an unmet need for new anemia therapeutics, this particular drug carried too strong of a safety signal for thrombotic risk in a non-dialysis dependent patient population.

Read more, here.

Loading
Publicado el

How Does Phosphate Binder Type Affect the Heart in Hemodialysis?

Loading

“Trial compared calcium-based vs non-calcium-based binders.

Non-calcium-based phosphate binders weren’t any better at reducing cardiovascular events than calcium-based binders in dialysis patients, the LANDMARK trial determined.

In the open-label randomized trial of over 2,300 Japanese patients on hemodialysis, there were no significant differences in composite cardiovascular events between the lanthanum carbonate group versus the calcium carbonate group (HR 1.11, 95% CI 0.88-1.41, P=0.37), reported Hiroaki Ogata, MD, of Showa University Northern Yokohama Hospital in Kanagawa, Japan, and colleagues.”

Read more, here.

Loading
Publicado el

Post-transplant health & wellness webinar (part 2)

Loading

Health and wellness continues long after receiving an organ transplant. Learn about post-transplant health from UNOS Medical Director David Klassen, M.D., Filza Hussain, M.D., of Stanford University, and Koren Axelrod of CareDx. This is the third webinar in our Transplantation Journey series.

Watch the webinar, here.

Loading
Publicado el

Heart, Death Risks Linked With CKD-Related Iron Deficiency

Loading

Regardless of anemia, iron deficiency in patients with late-stage chronic kidney disease (CKD) was linked with adverse health outcomes, an observational study found.

In 5,145 patients with stage 3-5 CKD not on dialysis, a transferrin saturation (TSAT) of 15% or less was associated with a higher risk for all-cause mortality before reaching dialysis or kidney transplant, as compared to TSAT levels of 26-35% (HR 1.44, 95% CI 1.03-2.01), according to Roberto Pecoits-Filho, MD, PhD, of the Arbor Research Collaborative for Health in Ann Arbor, Michigan, and colleagues.

Read more, here.

Loading
Publicado el

MAYO CLINIC STUDY EXPANDS CRITERIA TO BE A LIVING KIDNEY DONOR

Loading

Mayo Clinic says the pool of people who can be living kidney donors has expanded following the results of a recent study. Doctors say the results can help save more lives.

Previously transplant physicians were concerned about transplanting kidneys from patients with high blood pressure because of the possible long-term health impacts to them while living with just one kidney.

The study from Mayo Clinic included more than 100 patients and was conducted over 20 years. Dr. Mark Stegall, the Professor of Surgery at Mayo Clinic Rochester, says researchers found certain individuals with controlled hypertension can safely donate a kidney.

Read more, here.

Loading
Publicado el

What Evidence Do We Need to Move Forward With COVID Boosters?

Loading

“More data and an evaluation of several factors at home and abroad are key.

On Monday, employees of Pfizer met with high level executives in the Biden administration to discuss the role of boosters — a.k.a. a third vaccination with an mRNA vaccine for SARS-CoV-2. Some have speculated that, as with the first two doses, the emergency use authorization pathway will again be used to market boosters. With the rise of the Delta variant and others, enthusiasm in the media and the Twitter commentariat for boosters is growing. However, there are certain criteria that must be met before we jump on the booster bandwagon. Some of these criteria apply at home, and others apply abroad.”

Learn more, here.

Loading
Publicado el

J&J Recalls Aveeno, Neutrogena Spray Sunscreens

Loading

“Johnson & Johnson is recalling most of its Neutrogena and Aveeno spray sunscreens from U.S. stores after detecting benzene, a potentially cancer-causing chemical, in some samples.

J&J said Wednesday consumers should stop using and discard five of its six Neutrogena and Aveeno spray sunscreens. The company said it is also notifying distributors and retailers to stop selling the products, and arranging for the return of the products.

A company spokesman said the effort would include removing products from shelves.”

Read more about the recall and what to do, here.

Loading
Publicado el

Factors ID’d for COVID-19 Infection Risk in Dialysis Patients

Loading

“For individuals receiving in-center hemodialysis, the risk for having a positive test for infection or admission with suspected COVID-19 is associated with age, diabetes, local community COVID-19 rates, and dialysis unit size, according to a study published online in the Clinical Journal of the American Society of Nephrology.

Ben Caplin, MBChB, PhD, from University College London, and colleagues explored the role of variables such as community disease burden, dialysis unit attributes, and infection control strategies among patients receiving in-center hemodialysis between March 2 and May 31, 2020. Data were included for 5755 patients receiving dialysis in 51 units. Outcomes were defined as a positive test for infection or admission to the hospital with suspected COVID-19.”

Read more, here.

Loading
Publicado el

FDA Approves Drug to Reduce Risk of Serious Kidney and Heart Complications in Adults with Chronic Kidney Disease Associated with Type 2 Diabetes

Loading

“FDA has approved Kerendia (finerenone) tablets to reduce the risk of kidney function decline, kidney failure, cardiovascular death, non-fatal heart attacks, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes.

Diabetes is the leading cause of chronic kidney disease and kidney failure in the United States. Chronic kidney disease occurs when the kidneys are damaged and cannot filter blood normally. Because of defective filtering, patients can have complications related to fluid, electrolytes (minerals required for many bodily processes), and waste build-up in the body. Chronic kidney disease sometimes can progress to kidney failure. Patients also are at high risk of heart disease.”

Read the full report by the FDA, here.

Loading